Schedule 13G ownership disclosure

REIN THERAPEUTICS INC

Common Stock, $0.001 par value · CUSIP: 00887A204

Event date: 2025-05-08

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Voss Value Master Fund, LP

    Shares: 583,206.00 · Class: 2.5%

  • Voss Value-Oriented Special Situations Fund, LP

    Shares: 316,768.00 · Class: 1.4%

  • Voss Advisors GP, LLC

    Shares: 899,974.00 · Class: 3.9%

  • Voss Capital, LP

    Shares: 1,277,856.00 · Class: 5.6%

  • Cocke Travis W.

    Shares: 1,277,856.00 · Class: 5.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-25-001483
Form type
SCHEDULE 13G
Filer
Rein Therapeutics, Inc.
CIK
CIK 1420565
Filed
May 14, 2025
Reporting period
May 08, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub